Calcimedica, INC Form 4 insider transactions

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports the purchase of 53,333 shares of common stock at $3.75 per share on November 1, 2024.

Director Robert N. Wilson reports the acquisition of 53,333 shares of CalciMedica, Inc. common stock at a price of $3.75 per share on November 1, 2024.

Michael J. Dunn, President and COO of CalciMedica, Inc., exercised stock options to acquire 11,761 shares of common stock at $1.39 per share.

Director Frederic Guerard acquired 10,000 stock options in CalciMedica, Inc. at an exercise price of $4.16 on August 27, 2024.

Director Eric Bjerkhot acquired 10,000 stock options in CalciMedica, Inc. on August 27, 2024.

Director Allan Shaw acquired stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16 on August 27, 2024.

Director Fred A. Middleton receives stock options in CalciMedica, Inc.

Director Robert N. Wilson reports acquisition of stock options in CalciMedica, Inc.

Michael J. Dunn, President and COO of CalciMedica, Inc., reports the acquisition of employee stock options.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reports the acquisition of employee stock options.

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports the acquisition of stock options.

Sudarshan Hebbar, Chief Medical Officer of CalciMedica, acquired stock options for 82,500 shares on August 27, 2024.

CalciMedica's CEO, Rachel Leheny, reports the acquisition of 115,000 employee stock options.

CalciMedica's CEO, Rachel Leheny, recently purchased 1,000 shares of the company's common stock at an average price of $4.1898 per share.

Eric W. Roberts, Chief Business Officer of CalciMedica, recently acquired additional shares of the company's common stock through multiple transactions.

Director Robert N. Wilson of CalciMedica, Inc. recently purchased 54,000 shares of common stock at an average price of $3.719 per share.

Eric W. Roberts, Chief Business Officer of CalciMedica, recently acquired 5,000 shares of common stock at $4.04 per share, increasing his beneficial ownership.

Director Robert N. Wilson of CalciMedica, Inc. purchased 51,278 shares of common stock at an average price of $3.52 on June 28, 2024.

Director Robert N. Wilson of CalciMedica, Inc. reports purchasing 8,443 shares of common stock at an average price of $3.234.

Eric W. Roberts, Chief Business Officer of CalciMedica, recently acquired 5,000 shares of common stock at $3.22 per share, increasing his total holdings.

Daniel E. Geffken, Interim CFO of CalciMedica, Inc., reports the acquisition of warrants exercisable for 10,000 shares of common stock.

Director Frederic Guerard received stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16, vesting monthly over one year.

Director Eric Bjerkhult received stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16 on March 28, 2024.

Director Allan Shaw acquired stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16 on March 28, 2024.

Director Fred A. Middleton receives stock options for 10,000 shares in CalciMedica, Inc.

Director Robert N. Wilson of CalciMedica, Inc. reports acquisition of stock options.

Michael J. Dunn, President and COO of CalciMedica, reports the acquisition of employee stock options.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., acquired employee stock options on March 28, 2024.

Eric W. Roberts, Chief Business Officer of CalciMedica, reports the acquisition of stock options.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, reports the acquisition of stock options.